Trending: Abbott Earnings Decline on Lower Covid Test Sales
25 Januar 2023 - 9:51PM
Dow Jones News
15:21 ET -- Abbott Laboratories is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. It reported lower quarterly earnings but
noted that full-year results "significantly exceeded the EPS
guidance" provided at the beginning of 2022. For the fourth
quarter, adjusted earnings per share declined to $1.03 from $1.32
and Covid-19 testing-related sales fell to $1.07 billion from $2.32
billion. Abbott said the shift of the pandemic to an endemic state
has resulted in "significantly lower expected demand" for tests.
Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
January 25, 2023 15:36 ET (20:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024